Fang Zheng

Fang Zheng

Auto-generated profile, based on publicly available information

Fang Zheng

Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute On Eye Diseases, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2026 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
FZFang Zheng
Fang Zheng
EMElie Motulsky
Elie Motulsky
LRLuiz Roisman
Luiz Roisman
XFXiaoyun Fang
Xiaoyun Fang
KFKanae Fukutsu
Kanae Fukutsu
GTGavin Sw Tan
Gavin Sw Tan
Proliferative vitreoretinopathy (PVR) remains a major barrier in vitreoretinal surgery, being the leading cause of recurrent retinal detachment and surgical failure. PVR arises from abnormal wound healing, involving epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells, hyalocytes trans-differentiation into myofibroblasts, and dysregulated interactions among cytokines, growth factors, and chemokines. These lead to extracellular matrix remodeling and contractile membrane formation. Recent advancements have deepened insight into disease mechanisms and supported preclinical testing of therapies. Despite surgical progress, adjunctive treatments such as corticosteroids, antimetabolites, retinoids, and biologics show limited and inconsistent benefits in clinical trials. Emerging tools like proteomic biomarkers and advanced imaging offer promise for early risk detection and personalized care. However, major challenges remain in understanding disease complexity and improving tailored treatment outcomes. This review emphasizes the urgent need for targeted molecular therapies. Bridging basic science with clinical innovation will be key to advancing PVR management and preserving vision.

1 April 2026 in Patient Preference and Adherence
Verified
Journal Article
Open access
HCHaiyan Cai
Haiyan Cai
JXJingjie Xu
Jingjie Xu
JHJingliang He
Jingliang He
ASAiling Sui
Ailing Sui
PZPei Zhang
Pei Zhang
FZFang Zheng
Fang Zheng
To assess whether preoperative viewing of an educational procedural video reduces the incidence and severity of subconjunctival hemorrhage (SCH) following intravitreal anti-VEGF injections (IVI), and improves patient experience. In this surgeon-blind randomized controlled trial conducted at a single tertiary care center (NCT07002372), treatment-naïve patients scheduled for their first IVI were prospectively enrolled and randomized to either an intervention group (video viewing) or a control group (no video viewing). All participants completed the State-Trait Anxiety Inventory-State (STAI-S) before and after the injection. SCH incidence and area were assessed via standardized post-injection photographs analyzed using ImageJ software. Additional outcomes included patient-reported pain scores, heart rate, procedure time, and surgeon-rated cooperation. A total of 108 patients were enrolled, of whom 103 completed the study, which was fewer than the initially planned sample size. Baseline demographics were similar between groups. SCH occurred in 21/51 (41.2%) patients in the intervention group versus 36/52 (69.2%) in the control group (P = 0.004), though SCH area did not differ significantly. Logistic regression analysis revealed that the use of anticoagulant medication was positively associated with the occurrence of SCH (OR = 3.252; 95% CI, 1.166–9.071; P = 0.024), whereas watching an educational video prior to IVI was associated with a lower risk of SCH (OR = 0.275; 95% CI, 0.115–0.656; P = 0.004). Anxiety scores decreased post-procedure in both groups. In the intervention group, anxiety decreased modestly after video viewing (28.54 ± 10.40 to 27.00 ± 8.78, P = 0.052). Patients rated the video as helpful for understanding (8.75/10), calming nerves (8.44/10), and improving cooperation (8.55/10). No significant differences were observed in pain scores, heart rate, procedure time, or surgeon-rated cooperation. Preoperative procedural video viewing reduces the incidence of SCH and improves patients’ understanding of IVI. Given its simplicity and ease of implementation, this approach may serve as a practical adjunct to enhance patient experience in clinical practice.

25 May 2026 in Eye
Verified
Journal Article
Open access
FZFang Zheng
Fang Zheng
JXJingjie Xu
Jingjie Xu
YHYabo Han
Yabo Han
YXYufeng Xu
Yufeng Xu
SWShijing Wu
Shijing Wu
XFXiaoyun Fang
Xiaoyun Fang
Purpose: To identify baseline predictors of early submacular haemorrhage (SMH) displacement following intravitreal injection of C3F8, recombinant tissue plasminogen activator (rt-PA), and ranibizumab in patients with polypoidal choroidal vasculopathy (PCV). Methods: In this retrospective case-control study, swept-source OCT scans were analysed before and one week after treatment. SMH displacement was classified as incomplete (Group 1) or complete (Group 2) based on fundus photography and OCT. Clinical characteristics and OCT-derived parameters were evaluated for associations with displacement status. Results: Fifty-one eyes from 51 PCV patients were included. All eyes demonstrated some degree of SMH displacement after treatment, with 33 eyes showing incomplete displacement (residual SMH under the fovea: 80–768 μm) and 18 eyes showing complete displacement. Group 2 had better baseline visual acuity, and baseline LogMAR BCVA was negatively correlated with displacement grade. Group 2 also exhibited larger initial SMH volume and lower contrast-to-noise ratio (CNR), both associated with greater displacement. Although baseline PED volumes were similar, PED regression was more pronounced in Group 2. Conclusion: Complete SMH displacement was associated with better baseline vision, lower CNR, larger haemorrhage volume, and greater PED regression. Baseline BCVA, CNR, and SMH volume may serve as predictive factors for early SMH displacement following treatment.

13 October 2026 in Eye
Verified
Journal Article
Closed access
PDF file
MSMingzhi Su
Mingzhi Su
WZWeixin Zheng
Weixin Zheng
NHNingxi Hong
Ningxi Hong
FZFang Zheng
Fang Zheng
JXJun Xiao
Jun Xiao
PYPanpan Ye
Panpan Ye